Dynamic-susceptibility contrast MRI (DSC-MRI) is the most commonly used advanced imaging technique for the evaluation of high-grade glioma. Specifically, relative cerebral blood volume (rCBV) parameter maps, derived from DSC-MRI, provide information relevant to tumor diagnosis and treatment evaluation. For diagnosis, rCBV has been shown to correlate with tumor grade, the status of molecular markers and is useful for guiding surgical tissue sampling. rCBV provides key information for the evaluation of high-grade brain tumors in response to adjuvant chemo-radiation therapy (CRT) and anti-angiogenic therapies and is able to distinguish tumor from treatment effect, addressing a fundamental question for treatment management today. As such, the goal of this Research Topic is to raise awareness, and promote more widespread adoption of this important technology for the routine management of high-grade glioma.
As stated above, DSC-MRI is a proven technology useful for the diagnosis and evaluation of high-grade glioma. Despite the wealth of evidence it remains underutilized and is often considered optional for treatment management. The goal therefore is to motivate more widespread use throughout treatment management. This goal will be addressed by providing a focused edition highlighting both the proven and potential clinical benefits of DSC-MRI that cannot be obtained with standard imaging alone.
Papers should address the role of DSC-MRI to guide diagnoses through spatial guidance for surgical sampling and/or pathologic assessment for the determination of grading and molecular markers. Understanding the role of DSC-MRI to evaluate treatment response especially in the context of confounding situations, on standard MRI, such as pseudoprogression and pseudoresponse are of critical importance. Papers that also affirm the robustness of the technology, its accuracy and reproducibility would also be important to include as they would help to improve confidence in its routine clinical use. And finally, papers that discuss the value-add of DSC-MRI to routine clinical assessment would further support the goal of this edition.
Topics of interest include:
1. Original research using DSC-MRI in primary or metastatic brain tumors.
2. DSC-MRI in pre/post-surgery, newly diagnosed or recurrent tumors being treated with any approved or experimental treatment protocol.
3. Evaluation of DSC-MRI as a surrogate marker for molecular markers.
4. Utility of DSC-MRI to guide surgery, chemo and/or radiation therapy or distinguish tumor from treatment effect.
5. Any clinical assessment of DSC-MRI regarding information provided or ease of use.
Please note the following are out of scope for this Research Topic:
-Papers not using DSC-MRI
-Review Articles
-Meta-analyses
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Dynamic-susceptibility contrast MRI (DSC-MRI) is the most commonly used advanced imaging technique for the evaluation of high-grade glioma. Specifically, relative cerebral blood volume (rCBV) parameter maps, derived from DSC-MRI, provide information relevant to tumor diagnosis and treatment evaluation. For diagnosis, rCBV has been shown to correlate with tumor grade, the status of molecular markers and is useful for guiding surgical tissue sampling. rCBV provides key information for the evaluation of high-grade brain tumors in response to adjuvant chemo-radiation therapy (CRT) and anti-angiogenic therapies and is able to distinguish tumor from treatment effect, addressing a fundamental question for treatment management today. As such, the goal of this Research Topic is to raise awareness, and promote more widespread adoption of this important technology for the routine management of high-grade glioma.
As stated above, DSC-MRI is a proven technology useful for the diagnosis and evaluation of high-grade glioma. Despite the wealth of evidence it remains underutilized and is often considered optional for treatment management. The goal therefore is to motivate more widespread use throughout treatment management. This goal will be addressed by providing a focused edition highlighting both the proven and potential clinical benefits of DSC-MRI that cannot be obtained with standard imaging alone.
Papers should address the role of DSC-MRI to guide diagnoses through spatial guidance for surgical sampling and/or pathologic assessment for the determination of grading and molecular markers. Understanding the role of DSC-MRI to evaluate treatment response especially in the context of confounding situations, on standard MRI, such as pseudoprogression and pseudoresponse are of critical importance. Papers that also affirm the robustness of the technology, its accuracy and reproducibility would also be important to include as they would help to improve confidence in its routine clinical use. And finally, papers that discuss the value-add of DSC-MRI to routine clinical assessment would further support the goal of this edition.
Topics of interest include:
1. Original research using DSC-MRI in primary or metastatic brain tumors.
2. DSC-MRI in pre/post-surgery, newly diagnosed or recurrent tumors being treated with any approved or experimental treatment protocol.
3. Evaluation of DSC-MRI as a surrogate marker for molecular markers.
4. Utility of DSC-MRI to guide surgery, chemo and/or radiation therapy or distinguish tumor from treatment effect.
5. Any clinical assessment of DSC-MRI regarding information provided or ease of use.
Please note the following are out of scope for this Research Topic:
-Papers not using DSC-MRI
-Review Articles
-Meta-analyses
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.